DiagnostykaFRA:7JS +1.17%19 EV-to-FCF is 20.36 as of Jul. 05, 2026, which is 3% above its 10-year median of 19.83. GuruFocus rates FRA:7JS with a GF Score™ of 19/100. The stock has 1 warning sign investors should review. Among 98 Medical Diagnostics & Research companies, Diagnostyka ranks better than 59.18% on this metric.
EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Diagnostyka's Enterprise Value is €1,683.3 Mil.
Diagnostyka's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was €82.7 Mil. Therefore, Diagnostyka's EV-to-FCF for today is 20.36.
The historical rank and industry rank for Diagnostyka's EV-to-FCF or its related term are showing as below:
FRA:7JS'
s EV-to-FCF Range Over the Past 10 Years
Min: 17.15 Med: 19.83 Max: 22.42
Current: 20.2
During the past 5 years, the highest EV-to-FCF of Diagnostyka was 22.42. The lowest was 17.15. And the median was 19.83.
FRA:7JS's EV-to-FCF is ranked better than 59.18% of 98
companies
in the Medical Diagnostics & Research industry
Industry Median: 22.975
vs FRA:7JS: 20.20
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Diagnostyka's PE Ratio (TTM) for today is calculated as:
Diagnostyka's share price for today is €41.36.
Diagnostyka's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €1.795.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Diagnostyka EV-to-FCF Related Terms
Diagnostyka EV-to-FCF Historical Data
* Premium members only.
The historical data trend for Diagnostyka's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Diagnostics & Research subindustry, Diagnostyka's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Diagnostyka EV-to-FCF vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Diagnostyka's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Diagnostyka's EV-to-FCF falls into.
Diagnostyka's current Enterprise Value is €1,683.3 Mil.
Diagnostyka's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was €82.7 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Diagnostyka (FRA:7JS) has a EV-to-FCF of 20.36 as of Jul. 05, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diagnostyka and its competitors. This is near median its historical median of 19.83. Over the past decade, Diagnostyka's EV-to-FCF has ranged from 17.15 to 22.42. According to the industry distribution chart, Diagnostyka ranks #40 out of 98 companies in the Medical Diagnostics & Research industry, placing it in the top 40.8%.
Is Diagnostyka's EV-to-FCF too high?
Diagnostyka's current EV-to-FCF of 20.36 is near median its 10-year median of 19.83. Over the past 10 years, this metric has ranged from a low of 17.15 to a high of 22.42. The Medical Diagnostics & Research industry median EV-to-FCF is 22.98. Diagnostyka's value of 20.36 is 11.4% below this industry median. Based on the distribution chart, Diagnostyka ranks #40 out of 98 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, Diagnostyka has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Diagnostyka's EV-to-FCF compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Diagnostyka ranks #40 out of 98 companies for EV-to-FCF. This puts Diagnostyka in the upper half of its industry. The industry median EV-to-FCF is 22.98. Diagnostyka's value of 20.36 is 11.4% below this benchmark. Historically, Diagnostyka's own EV-to-FCF has ranged from 17.15 to 22.42 over the past decade. While the company's 10-year median is 19.83 vs. the industry median of 22.98, Diagnostyka has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Medical Diagnostics & Research company?
The median EV-to-FCF among Medical Diagnostics & Research companies is 22.98, based on 98 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Diagnostyka's current EV-to-FCF of 20.36 is 11.4% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on Diagnostyka and its competitors. For the Medical Diagnostics & Research industry, the median EV-to-FCF is 22.98 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Diagnostyka's current EV-to-FCF is 20.36, which is near median its own 10-year median of 19.83. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Diagnostyka stock overvalued right now?
Diagnostyka (FRA:7JS) has a current EV-to-FCF of 20.36. The current EV-to-FCF is 20.36, which is near median its 10-year median of 19.83 and 11.4% below the Medical Diagnostics & Research industry median of 22.98. Diagnostyka's overall GF Score™ is 19/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For Diagnostyka (FRA:7JS), the current EV-to-FCF is 20.36 as of Jul. 05, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Diagnostyka SA is engaged in providing laboratory diagnostics services in Poland. The company offers comprehensive laboratory services from collecting biological material, through testing, to providing results online.
19GF Score
Get the complete analysis for FRA:7JS
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7JS has been successfully added to your 
